Magnetic Resonance Imaging in Cerebral Small Vessel Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05200377|
Recruitment Status : Recruiting
First Posted : January 20, 2022
Last Update Posted : July 20, 2022
|Condition or disease||Intervention/treatment|
|Cerebral Small Vessel Diseases MRI||Diagnostic Test: Magnetic resonance imaging|
|Study Type :||Observational|
|Estimated Enrollment :||300 participants|
|Official Title:||Magnetic Resonance Imaging in Cerebral Small Vessel Disease|
|Actual Study Start Date :||January 1, 2022|
|Estimated Primary Completion Date :||December 31, 2025|
|Estimated Study Completion Date :||December 31, 2025|
Cerebral small vessel disease group
Patients with clinically and radiologically evidenced cerebral small vessel disease. Patients are grouped by severity of cerebral small vessel disease assessed by comprehensive MRI findings.
Diagnostic Test: Magnetic resonance imaging
Patients recruited will receive Magnetic resonance imaging.
- Progression in total cerebral small vessel disease burden [ Time Frame: 1 year ]Total cSVD burden assessed by MRI
- Progression in congnitive impairments [ Time Frame: 1 years ]Global Z-score by cognitive domain
- Recurrent ischemic events [ Time Frame: 1 year ]Recurrent ischemic stroke, TIA and vascular death
- Modified Rankin Scale [ Time Frame: 90 days and 1 year after qualifying event ]Disability assessed by modified Rankin Scale (mRS). The scores, ranging from 0 (no symptoms) to 6 (death), were recorded by phone call or outpatient consultation. A favorable outcome was defined as mRS score 0-2, unfavorable outcome was defined as mRS score > 2.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05200377
|Contact: Kun Cheng, M.S.||+email@example.com|
|Chinese PLA General Hospital||Recruiting|
|Beijing, China, 100853|
|Contact: Kun Cheng, M.S. +86 19921784434 firstname.lastname@example.org|
|Principal Investigator:||Xin Lou, MD, PhD||Chinese PLA General Hospital|